BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38395907)

  • 1. Novel prognostic marker TGFBI affects the migration and invasion function of ovarian cancer cells and activates the integrin αvβ3-PI3K-Akt signaling pathway.
    Wang H; Xu YH; Guo Y
    J Ovarian Res; 2024 Feb; 17(1):50. PubMed ID: 38395907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ß3 integrin modulates transforming growth factor beta induced (TGFBI) function and paclitaxel response in ovarian cancer cells.
    Tumbarello DA; Temple J; Brenton JD
    Mol Cancer; 2012 May; 11():36. PubMed ID: 22640878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIF-2α-dependent TGFBI promotes ovarian cancer chemoresistance by activating PI3K/Akt pathway to inhibit apoptosis and facilitate DNA repair process.
    Ma S; Wang J; Cui Z; Yang X; Cui X; Li X; Zhao L
    Sci Rep; 2024 Feb; 14(1):3870. PubMed ID: 38365849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K/AKT pathway in bladder cancer.
    Chi M; Liu J; Mei C; Shi Y; Liu N; Jiang X; Liu C; Xue N; Hong H; Xie J; Sun X; Yin B; Meng X; Wang B
    J Exp Clin Cancer Res; 2022 May; 41(1):175. PubMed ID: 35581606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition.
    Lu DH; Yang J; Gao LK; Min J; Tang JM; Hu M; Li Y; Li ST; Chen J; Hong L
    Oncol Rep; 2019 Feb; 41(2):917-927. PubMed ID: 30483796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 14, 15-EET induces breast cancer cell EMT and cisplatin resistance by up-regulating integrin αvβ3 and activating FAK/PI3K/AKT signaling.
    Luo J; Yao JF; Deng XF; Zheng XD; Jia M; Wang YQ; Huang Y; Zhu JH
    J Exp Clin Cancer Res; 2018 Feb; 37(1):23. PubMed ID: 29426357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HYOU1 promotes cell growth and metastasis via activating PI3K/AKT signaling in epithelial ovarian cancer and predicts poor prognosis.
    Li X; Zhang NX; Ye HY; Song PP; Chang W; Chen L; Wang Z; Zhang L; Wang NN
    Eur Rev Med Pharmacol Sci; 2019 Jan; 23(10):4126-4135. PubMed ID: 31173282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced Expression of TGFBI Promotes the Proliferation and Migration of Glioma Cells.
    Guo SK; Shen MF; Yao HW; Liu YS
    Cell Physiol Biochem; 2018; 49(3):1097-1109. PubMed ID: 30196284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial-mesenchymal transition interlinked with reprogrammed metabolism.
    Leung D; Price ZK; Lokman NA; Wang W; Goonetilleke L; Kadife E; Oehler MK; Ricciardelli C; Kannourakis G; Ahmed N
    J Transl Med; 2022 Dec; 20(1):556. PubMed ID: 36463238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.
    Bugide S; Gonugunta VK; Penugurti V; Malisetty VL; Vadlamudi RK; Manavathi B
    Cell Oncol (Dordr); 2017 Apr; 40(2):133-144. PubMed ID: 28039608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transforming growth factor-β-induced protein (TGFBI) suppresses mesothelioma progression through the Akt/mTOR pathway.
    Wen G; Hong M; Li B; Liao W; Cheng SK; Hu B; Calaf GM; Lu P; Partridge MA; Tong J; Hei TK
    Int J Oncol; 2011 Oct; 39(4):1001-9. PubMed ID: 21701776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis.
    Lu C; Shan Z; Hong J; Yang L
    Int J Oncol; 2017 Jul; 51(1):235-244. PubMed ID: 28534966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TRPM7 promotes the epithelial-mesenchymal transition in ovarian cancer through the calcium-related PI3K / AKT oncogenic signaling.
    Liu L; Wu N; Wang Y; Zhang X; Xia B; Tang J; Cai J; Zhao Z; Liao Q; Wang J
    J Exp Clin Cancer Res; 2019 Feb; 38(1):106. PubMed ID: 30819230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. UBE2S promotes the development of ovarian cancer by promoting PI3K/AKT/mTOR signaling pathway to regulate cell cycle and apoptosis.
    Zhang M; Liu Y; Yin Y; Sun Z; Wang Y; Zhang Z; Li F; Chen X
    Mol Med; 2022 Jun; 28(1):62. PubMed ID: 35658829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.
    Karlan BY; Dering J; Walsh C; Orsulic S; Lester J; Anderson LA; Ginther CL; Fejzo M; Slamon D
    Gynecol Oncol; 2014 Feb; 132(2):334-42. PubMed ID: 24368280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. γ-Glutamyl cyclotransferase contributes to tumor progression in high grade serous ovarian cancer by regulating epithelial-mesenchymal transition via activating PI3K/AKT/mTOR pathway.
    Li Y; Wu T; Wang Y; Yang L; Hu C; Chen L; Wu S
    Gynecol Oncol; 2018 Apr; 149(1):163-172. PubMed ID: 29429592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High expression of PXDN is associated with poor prognosis and promotes proliferation, invasion as well as migration in ovarian cancer.
    Zheng YZ; Liang L
    Ann Diagn Pathol; 2018 Jun; 34():161-165. PubMed ID: 29661721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TCP1 regulates PI3K/AKT/mTOR signaling pathway to promote proliferation of ovarian cancer cells.
    Weng H; Feng X; Lan Y; Zheng Z
    J Ovarian Res; 2021 Jun; 14(1):82. PubMed ID: 34162426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upregulation of lncRNA AB073614 functions as a predictor of epithelial ovarian cancer prognosis and promotes tumor growth in vitro and in vivo.
    Zeng S; Liu S; Feng J; Gao J; Xue F
    Cancer Biomark; 2019; 24(4):421-428. PubMed ID: 30909184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CEP55 promotes epithelial-mesenchymal transition in renal cell carcinoma through PI3K/AKT/mTOR pathway.
    Chen H; Zhu D; Zheng Z; Cai Y; Chen Z; Xie W
    Clin Transl Oncol; 2019 Jul; 21(7):939-949. PubMed ID: 30607788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.